Powered by the Evidence-based Practice Centers
SHARE:
FacebookTwitterFacebookPrintShare

Pharmacokinetic/Pharmacodynamic Measures for Guiding Antibiotic Treatment for Hospital-Acquired Pneumonia

Systematic Review ARCHIVED Nov 24, 2014

Documents

People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.

Archived: This report is greater than 3 years old. Findings may be used for research purposes, but should not be considered current.

Structured Abstract

Objective

To conduct a systematic review of the use of pharmacokinetic/pharmacodynamic (PK/PD) measures or strategies to dose and monitor intravenous (IV) antibiotics in the treatment of adults with hospital-acquired pneumonia (HAP).

Data sources

MEDLINE® (via PubMed), Cochrane Library, International Pharmaceutical Abstracts, and ClinicalTrials.gov from January 1, 2004, to June 7, 2014.

Review method

Two investigators independently selected, extracted data from, and rated risk of bias of studies. We graded strength of evidence based on established guidance.

Results

Ten studies (seven trials, three cohort studies) met inclusion criteria. Evidence is insufficient to conclude whether using PK/PD measures to inform decisions about dosing or monitoring IV antibiotic treatment improves either intermediate or health outcomes. One trial (rated high risk of bias) used PK/PD measures to study the impact of different antibiotic dosing levels on clinical responses, such as time on mechanical ventilation, treatment failure, and mortality.

Evidence is also insufficient to draw conclusions about the effect of continuous infusions of beta-lactam antibiotics compared with the effect of intermittent infusions on outcomes related to clinical response, mechanical ventilation, morbidity, mortality, or rates of antibiotic-related adverse events. Clinical response, duration of mechanical ventilation, superinfection, rates of antibiotic-related adverse events, and infusion-related adverse effects did not differ significantly in any study.

Conclusions

Despite the theoretical advantages of optimizing IV antibiotic dosing using PK/PD principles in patients with HAP, major gaps in the available evidence preclude our drawing conclusions or explaining clinical or policy implications. The near absence of strong evidence, particularly related to clinical applications, limits our ability to either support or oppose the adoption of various PK/PD strategies for this specific clinical purpose.

Project Timeline

Pharmacokinetic/ Pharmacodynamic Measures for Guiding Antibiotic Treatment for Hospital-Acquired Pneumonia

Mar 22, 2013
Topic Initiated
Jul 19, 2013
Nov 24, 2014
Systematic Review Archived
Page last reviewed December 2019
Page originally created November 2017

Internet Citation: Systematic Review: Pharmacokinetic/Pharmacodynamic Measures for Guiding Antibiotic Treatment for Hospital-Acquired Pneumonia. Content last reviewed December 2019. Effective Health Care Program, Agency for Healthcare Research and Quality, Rockville, MD.
https://effectivehealthcare.ahrq.gov/products/pneumonia-antibiotic-treatment/research

Select to copy citation